View Older Stories View More Recent Stories
-
Antios Therapeutics Raises $75 Million in a Series B-1 Funding to Advance Clinical Programs for HBV
-
Form SC 13D/A Forma Therapeutics Holdi Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D/A Kala Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
PepGen Appoints Noel Donnelly as Chief Financial Officer
-
Form SC 13G OTONOMY, INC. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G Pyxis Oncology, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Cedilla Therapeutics Completes $82.6M Series B Financing
-
PepGen Welcomes Esteemed Neurologist Dr. John Day to Scientific Advisory Board
-
AavantiBio Furthers Strategic Partnership with University of Florida to Research and Develop Next Generation Gene Therapy Capsids
-
DTx Pharma to Participate in the 8th Annual Fall Private Company Showcase with Solebury Trout and BMO
-
RA Capital Management, LP Closes $880 Million Venture Capital Fund
-
DTx Pharma to Present at the OIS Retina Innovation Showcase
-
Delix Therapeutics Named One of Fierce Biotech’s “Fierce 15” Companies of 2021
-
Delix Therapeutics Named One of Fierce Biotech's "Fierce 15" Companies of 2021
-
Form SC 13G SYNLOGIC, INC. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Expansion Therapeutics Raises $80 Million Series B Financing to Treat Neurodegenerative Diseases
-
Nucleate launches nationwide to empower the next generation of biotech leaders
-
Form SC 13D DICE Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D Tyra Biosciences, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Delix Therapeutics Closes $70 Million Series A Financing to Advance Pipeline of Novel Psychoplastogen Therapeutics to Treat Brain Disorders
-
Hemab Appoints Mads Behrndt as Chief Financial Officer
-
PepGen To Present Research on Enhanced Delivery Treatments for Neuromuscular Disease at Two Scientific Conferences in September
-
DTx Pharma to Present at Upcoming Investor Conferences
-
Ivantis Announces Settlement of Glaukos Patent Litigation
-
Form SC 13D/A POINT Biopharma Global Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D/A Acumen Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Icosavax Reports Second Quarter 2021 Financial Results and Provides Corporate Update
-
Obsidian Therapeutics Announces Closing of $115 Million Series B Financing
-
Xenikos Secures €40 Million in Convertible Debt Financing, Veloxis Pharmaceuticals Joins as Strategic Investor
-
Catabasis Pharmaceuticals Announces New Company Name, Astria Therapeutics, Highlighting New Company Focus
-
HilleVax Closes $135 Million Crossover Financing to Advance Clinical Stage Norovirus Vaccine Candidate
-
Xenikos Secures €40 Million in Convertible Debt Financing, Veloxis Pharmaceuticals Joins as Strategic Investor
-
Xenikos Secures €40 Million in Convertible Debt Financing, Veloxis Pharmaceuticals Joins as Strategic Investor
-
Asher Bio Closes $108 Million Series B Financing
-
ARS Pharmaceuticals Raises $55 Million in Series D Funding for Launch Preparations of Neffy™ (epinephrine nasal spray)
-
PepGen Announces New Additions to Leadership Team and Board of Directors
-
DiCE Molecules Announces $60 Million Series C-1 Financing
-
Form SC 13G Aerpio Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D Eliem Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D/A Wave Life Sciences Ltd. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Jnana Therapeutics Closes $50 Million Series B Financing to Advance Lead PKU Program and Small Molecule Pipeline Based on Next Gen Chemoproteomic Platform
-
Form 13F-HR RA CAPITAL MANAGEMENT, For: Jun 30
-
Form SC 13G Adverum Biotechnologies, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G EyePoint Pharmaceuticals Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G RxSight, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D Icosavax, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
GentiBio Announces $157M Series A Financing to Advance Engineered Regulatory T cells as Transformative Therapeutics with Potential to Restore Immune Tolerance and Durably Treat Autoinflammation
-
Tango Therapeutics Debuts as Publicly Traded Precision Oncology Company Focused on the Next Generation of Targeted Cancer Therapies
-
Sydnexis Secures $45 Million Series B Financing Led by Visionary Ventures and Blue Stem Capital
-
Form SC 13G DA32 Life Science Tech Filed by: RA CAPITAL MANAGEMENT, L.P.
